EyePoint Pharmaceuticals Inc
Research EyePoint Pharmaceuticals Inc (EYPT) on Bullrun: market cap USD 425.76M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEYPT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 425.76M
- Financial periodQ2 2026
- RevenueUSD 507.00K
- Net income-USD 94.47M
- Free cash flow-USD 63.55M
- Gross margin100.0%
Valuation Snapshot
latest market cap is USD 425.76M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 31.37M | -USD 231.96M | -USD 243.39M | 93.4% | -3.17 | USD 101.82M | USD 20.77M | USD 306.11M |
| FY2024 | USD 43.27M | -USD 130.87M | -USD 130.28M | 91.4% | -2.32 | USD 99.70M | USD 21.86M | USD 336.50M |
| FY2023 | USD 46.02M | -USD 70.80M | -USD 1.61M | 89.9% | -1.82 | USD 281.26M | USD 0 | USD 266.32M |
| FY2022 | USD 41.40M | -USD 102.25M | -USD 67.16M | n/a | -2.74 | USD 95.63M | USD 39.79M | USD 96.37M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 425.76M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.51B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 508.58M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.13B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 119.29M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 415.01M | n/a | n/a | n/a |
About EyePoint Pharmaceuticals Inc
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is EyePoint Pharmaceuticals Inc's market cap?
EyePoint Pharmaceuticals Inc's market capitalization is USD 425.76M.
What does EyePoint Pharmaceuticals Inc do?
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.